➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Boehringer Ingelheim
Johnson and Johnson
Colorcon
Mallinckrodt

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00487240 ↗ Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes Completed Eli Lilly and Company Phase 3 2007-06-01 The purpose of this study is to examine the efficacy and safety of insulin lispro protamine suspension (ILPS) as compared to insulin detemir as basal insulin combined with mealtime insulin therapy in patients with type 1 diabetes. A gatekeeper strategy will be employed for sequentially testing the secondary objectives.
NCT00494013 ↗ Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY) Completed Eli Lilly and Company Phase 3 2007-08-01 The purpose of this study is to examine the effectiveness and safety of insulin lispro protamine suspension (ILPS) as compared to insulin detemir as basal insulin therapy in adults with type 2 diabetes. A gatekeeper strategy will be employed for sequentially testing the secondary objectives.
NCT00510952 ↗ Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE) Completed Eli Lilly and Company Phase 3 2007-08-01 The purpose of this study is to examine the effectiveness and safety of insulin lispro protamine suspension (ILPS) as compared to insulin glargine as basal insulin therapy in adults with type 2 diabetes.
NCT00560417 ↗ Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide Completed Eli Lilly and Company Phase 3 2007-11-01 This study will compare insulin lispro protamine suspension (ILPS) and insulin glargine in combination with the patient's oral diabetes medications and exenatide, for their ability to control blood sugar in patients with type 2 diabetes.
NCT00641407 ↗ Bedtime Insulins and Oral Antihyperglycemic Drugs in Type 2 Diabetes Completed Second University of Naples Phase 4 2007-01-01 The maintenance of nearly normal glycemic levels reduces the risk of diabetic complications, but is difficult to achieve, despite the administration of escalating doses of oral antidiabetic drugs, such as metformin, sulfonylureas, and thiazolidinediones. Most patients eventually require insulin which usually is added when glycemic control with a regimen of oral antidiabetic agents becomes suboptimal. The aims of the present study were: 1) To compare the clinical efficacy of insulin glargine and neutral protamine lispro (NPL) insulin when added to ongoing oral therapy in poorly controlled type 2 diabetic patients; 2) to find out the possibility to phenotype the patient who may benefit more by the single treatment. This an open-label, randomized, parallel, 36-week comparative study was performed between January 2007 and March 2008 at a single centre.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant

Condition Name

Condition Name for Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant
Intervention Trials
Diabetes Mellitus, Type 2 4
Type 2 Diabetes Mellitus 2
Diabetes Mellitus, Type 1 1
Diabetes Mellitus Type 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant
Intervention Trials
Diabetes Mellitus 8
Diabetes Mellitus, Type 2 7
Hypoglycemia 1
Diabetes Mellitus, Type 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant

Trials by Country

Trials by Country for Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant
Location Trials
United States 60
United Kingdom 4
Mexico 3
Greece 2
Australia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant
Location Trials
New York 3
Kentucky 3
Indiana 3
Florida 3
California 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant

Clinical Trial Phase

Clinical Trial Phase for Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant
Clinical Trial Phase Trials
Phase 4 2
Phase 3 6
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant
Clinical Trial Phase Trials
Completed 8
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant

Sponsor Name

Sponsor Name for Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant
Sponsor Trials
Eli Lilly and Company 5
Sanofi 1
Medical University of Graz 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant
Sponsor Trials
Industry 6
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
McKinsey
Johnson and Johnson
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.